Action Abivax - ABVX

Abivax SA (ABVX) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

92,80

( 2,94% )

Prix Achat

92,64

Prix Vente

92,82

Volume échangé

250 724

0,00 Fourchette du Jour 0,00

5,69 Plage de 52 semaines 148,83

Cap du marché

7,396B

Clôture Veille

90,15

Ouverture

Dernière Transaction

92.8

Dernière heure de transaction

15:06:49

Volume financier

VWAP

Volume moyen (3 m)

US$ 250 933

Actions en circulation

79 694 535

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-25,06

Bénéfice par action (BPA)

-4,52

Chiffre d'affairess (LTM)

4,92M

Bénéfice net (LTM)

-332,2M

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical devel... ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

www.abivax.com

Siège social

Paris, France

Fondé

2026

Abivax SA est coté dans le secteur Healthcare de la NASDAQ avec le ticker ABVX. Le dernier cours de clôture d'Abivax était de US$90,15. Au cours de la dernière année, les actions de Abivax ont été négociées dans une fourchette de prix de US$ 5,69 à US$ 148,83.

Abivax compte actuellement 79 694 535 actions en circulation. La capitalisation boursière d'Abivax est de US$7,40 milliard. Abivax a un ratio cours/bénéfice (ratio PE) de -25.06.

Flux global

Haussier

Prime nette

5M

Calls / Puts

737,50%

Ach. / Vent.

113,33%

OTM / ITM

131,03%

Sweeps Ratio

0,00%

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) PR...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to...

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-40.84	-30.5597126609	133.64	135.075	69.81	6812728	94.48667612	DR
4	-33.76	-26.6750948167	126.56	135.075	69.81	2539006	102.45569853	DR
12	-26.8512	-22.4412291728	119.6512	135.075	69.81	1502074	108.89909065	DR
26	-19.7	-17.5111111111	112.5	148.83	69.81	1436970	115.65482152	DR
52	84.6	1031.70731707	8.2	148.83	5.69	1357121	97.06130551	DR
156	81.2	700	11.6	148.83	4.77	608290	84.09912067	DR
260	81.2	700	11.6	148.83	4.77	608290	84.09912067	DR

ABVX - Frequently Asked Questions (FAQ)

What is the current Abivax SA share price?

The current share price of Abivax SA is US$ 92,80

How many Abivax SA shares are in issue?

Abivax SA has 79 694 535 shares in issue

What is the market cap of Abivax SA?

The market capitalisation of Abivax SA is USD 7,4B

What is the 1 year trading range for Abivax SA share price?

Abivax SA has traded in the range of US$ 5,69 to US$ 148,83 during the past year

What is the PE ratio of Abivax SA?

The price to earnings ratio of Abivax SA is -25,06

What is the cash to sales ratio of Abivax SA?

The cash to sales ratio of Abivax SA is 1,84k

What is the registered address of Abivax SA?

The registered address for Abivax SA is 7-11 Boulevard Haussmann, Paris, Ile-de-France, 75009

What is the Abivax SA website address?

The website address for Abivax SA is www.abivax.com

Which industry sector does Abivax SA operate in?

Abivax SA operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Abivax SA (ABVX)

Abivax SA (ABVX) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Abivax SA

Flux d'options Abivax (ABVX)

Flux global

Haussier

Prime nette

5M

Calls / Puts

737,50%

Ach. / Vent.

113,33%

OTM / ITM

131,03%

Sweeps Ratio

0,00%

ABVX Dernières nouvelles

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B7 - Prospectus [Rule 424(b)(7)]

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Shares Tumble Despite Strong Ulcerative Colitis Trial Results as Safety Concerns Emerge (ABVX)

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B7 - Prospectus [Rule 424(b)(7)]

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Form S-8 - Securities to be offered to employees in employee benefit plans

ABVX - Frequently Asked Questions (FAQ)

ABVX Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Inscrivez-vous GRATUITEMENT et obtenez:

Supprimer les publicités